+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

H2 Receptor Antagonist Global Market Report 2025

  • PDF Icon

    Report

  • 175 Pages
  • January 2025
  • Region: Global
  • The Business Research Company
  • ID: 6103705
The H2 receptor antagonist market size has grown strongly in recent years. It will grow from $4.08 billion in 2024 to $4.32 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the rising prevalence of peptic ulcers, widespread use of over-the-counter antacids, increasing diagnoses of gastroesophageal reflux disease (GERD), strong adoption in hospital settings, and a rising incidence of gastrointestinal disorders.

The H2 receptor antagonist market size is expected to see strong growth in the next few years. It will grow to $5.35 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The projected growth in the forecast period is driven by rising cases of lifestyle-related digestive disorders, increasing demand for non-prescription gastrointestinal treatments, a growing geriatric population with chronic acid issues, expanding availability of generic formulations, and the development of pediatric-friendly formulations. Key trends expected in the forecast period include the development of extended-release formulations, integration with digital health monitoring tools, innovation in pediatric dosage forms, combination therapies with probiotics, and advances in compound stability for hot climates.

The increasing incidence of gastrointestinal diseases is expected to drive the growth of the H2 receptor antagonist market. Gastrointestinal diseases are conditions that affect the digestive tract, including infections, inflammation, and disorders of the stomach and intestines. The rise in gastrointestinal diseases is largely attributed to unhealthy dietary habits and the increasing consumption of processed foods, which can disrupt gut health and lead to digestive disorders such as acid reflux, irritable bowel syndrome (IBS), and ulcers. H2 receptor antagonists address these conditions by blocking histamine receptors in the stomach, reducing acid production, and alleviating symptoms such as acid reflux, ulcers, and gastritis. For example, in January 2023, the American Cancer Society (ACS) reported a 3.18% increase in gastrointestinal cancer cases in the United States, rising from 338,090 in 2022 to 348,840 in 2023. As a result, the growing incidence of gastrointestinal diseases is driving the expansion of the H2 receptor antagonist market.

Companies in the H2 receptor antagonist market are focusing on developing innovative solutions, such as novel drug delivery systems, to improve the efficacy, convenience, and patient compliance of acid-suppressing treatments. Novel drug delivery systems are advanced technologies designed to release therapeutic agents in a controlled, targeted, and sustained manner for enhanced efficacy and better patient adherence. For instance, in June 2022, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Famotidine ODT, an orally disintegrating tablet for treating acid-related disorders such as GERD. This formulation allows patients, especially those with difficulty swallowing, to take the medication without water, improving convenience and compliance. Zydus highlighted that this innovation supports better treatment outcomes by making the medication easier to use and providing faster relief. The adoption of such delivery systems is helping to drive growth in the H2 receptor antagonist market by enhancing the therapeutic experience and accessibility for patients.

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition aims to strengthen Amgen’s position in rare diseases and immunology by expanding its portfolio with Horizon's innovative therapies and global commercial capabilities. Horizon Therapeutics, an Ireland-based company, manufactures H2 receptor antagonists, enhancing Amgen’s footprint in the gastrointestinal and inflammation treatment market.

Major players in the h2 receptor antagonist market are Pfizer Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Apotex Inc., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals plc, Lupin Ltd., Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Accord Healthcare Limited.

North America was the largest region in the H2 receptor antagonist market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in H2 receptor antagonist report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the H2 receptor antagonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The H2 receptor antagonist market consists of sales of tegoprazan and lansoprazole. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. H2 Receptor Antagonist Market Characteristics3. H2 Receptor Antagonist Market Trends And Strategies4. H2 Receptor Antagonist Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global H2 Receptor Antagonist Growth Analysis And Strategic Analysis Framework
5.1. Global H2 Receptor Antagonist PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global H2 Receptor Antagonist Market Growth Rate Analysis
5.4. Global H2 Receptor Antagonist Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global H2 Receptor Antagonist Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global H2 Receptor Antagonist Total Addressable Market (TAM)
6. H2 Receptor Antagonist Market Segmentation
6.1. Global H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cimetidine
  • Ranitidine
  • Famotidine
  • Nizatidine
6.2. Global H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gastroesophageal Reflux Disease (GERD)
  • Peptic Ulcers
  • Zollinger-Ellison Syndrome
  • Other Indications
6.3. Global H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Intravenous
  • Intramuscular
6.4. Global H2 Receptor Antagonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
6.5. Global H2 Receptor Antagonist Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Home Care Settings
7. H2 Receptor Antagonist Market Regional And Country Analysis
7.1. Global H2 Receptor Antagonist Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global H2 Receptor Antagonist Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific H2 Receptor Antagonist Market
8.1. Asia-Pacific H2 Receptor Antagonist Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China H2 Receptor Antagonist Market
9.1. China H2 Receptor Antagonist Market Overview
9.2. China H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India H2 Receptor Antagonist Market
10.1. India H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan H2 Receptor Antagonist Market
11.1. Japan H2 Receptor Antagonist Market Overview
11.2. Japan H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia H2 Receptor Antagonist Market
12.1. Australia H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia H2 Receptor Antagonist Market
13.1. Indonesia H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea H2 Receptor Antagonist Market
14.1. South Korea H2 Receptor Antagonist Market Overview
14.2. South Korea H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe H2 Receptor Antagonist Market
15.1. Western Europe H2 Receptor Antagonist Market Overview
15.2. Western Europe H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK H2 Receptor Antagonist Market
16.1. UK H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany H2 Receptor Antagonist Market
17.1. Germany H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France H2 Receptor Antagonist Market
18.1. France H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy H2 Receptor Antagonist Market
19.1. Italy H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain H2 Receptor Antagonist Market
20.1. Spain H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe H2 Receptor Antagonist Market
21.1. Eastern Europe H2 Receptor Antagonist Market Overview
21.2. Eastern Europe H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia H2 Receptor Antagonist Market
22.1. Russia H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America H2 Receptor Antagonist Market
23.1. North America H2 Receptor Antagonist Market Overview
23.2. North America H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA H2 Receptor Antagonist Market
24.1. USA H2 Receptor Antagonist Market Overview
24.2. USA H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada H2 Receptor Antagonist Market
25.1. Canada H2 Receptor Antagonist Market Overview
25.2. Canada H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America H2 Receptor Antagonist Market
26.1. South America H2 Receptor Antagonist Market Overview
26.2. South America H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil H2 Receptor Antagonist Market
27.1. Brazil H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East H2 Receptor Antagonist Market
28.1. Middle East H2 Receptor Antagonist Market Overview
28.2. Middle East H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa H2 Receptor Antagonist Market
29.1. Africa H2 Receptor Antagonist Market Overview
29.2. Africa H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. H2 Receptor Antagonist Market Competitive Landscape And Company Profiles
30.1. H2 Receptor Antagonist Market Competitive Landscape
30.2. H2 Receptor Antagonist Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
31. H2 Receptor Antagonist Market Other Major And Innovative Companies
31.1. Takeda Pharmaceutical Company Limited
31.2. Eli Lilly and Company
31.3. Viatris Inc.
31.4. Teva Pharmaceutical Industries Limited
31.5. Boehringer Ingelheim International GmbH
31.6. Sun Pharmaceutical Industries Limited
31.7. Apotex Inc.
31.8. Aurobindo Pharma Limited
31.9. Dr. Reddy's Laboratories Limited
31.10. Cipla Limited
31.11. Hikma Pharmaceuticals plc
31.12. Lupin Ltd.
31.13. Zydus Lifesciences Limited
31.14. Torrent Pharmaceuticals Limited
31.15. Accord Healthcare Limited
32. Global H2 Receptor Antagonist Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The H2 Receptor Antagonist Market34. Recent Developments In The H2 Receptor Antagonist Market
35. H2 Receptor Antagonist Market High Potential Countries, Segments and Strategies
35.1 H2 Receptor Antagonist Market In 2029 - Countries Offering Most New Opportunities
35.2 H2 Receptor Antagonist Market In 2029 - Segments Offering Most New Opportunities
35.3 H2 Receptor Antagonist Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright And Disclaimer

Executive Summary

H2 Receptor Antagonist Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on h2 receptor antagonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for h2 receptor antagonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The h2 receptor antagonist market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Drug Class: Cimetidine; Ranitidine; Famotidine; Nizatidine
2) By Route of Administration: Oral; Intravenous; Intramuscular
3) By Indication: Gastroesophageal Reflux Disease (GERD); Peptic Ulcers; Zollinger-Ellison Syndrome; Other Indications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
5) By End-User: Hospitals; Clinics; Home Care Settings

Key Companies Profiled: Pfizer Inc.; Sanofi S.A.; Abbott Laboratories; Novartis AG; GlaxoSmithKline plc

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

  • Pfizer Inc.
  • Sanofi S.A.
  • Abbott Laboratories
  • Novartis AG
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Viatris Inc.
  • Teva Pharmaceutical Industries Limited
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries Limited
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories Limited
  • Cipla Limited
  • Hikma Pharmaceuticals plc
  • Lupin Ltd.
  • Zydus Lifesciences Limited
  • Torrent Pharmaceuticals Limited
  • Accord Healthcare Limited